Abstract
Background:
Phenotypic heterogeneity is apparent among individuals with putative monogenic disease, such as familial hypertrophic cardiomyopathy. Genome sequencing (GS) allows interrogation of the full spectrum of inborn genetic variation in an individual and RNA profiling provides a snapshot of the cardiac-specific pathogenic effects on gene expression.
Objectives:
Identify candidate genetic modifiers of hypertrophic cardiomyopathy phenotype.
Methods:
We performed GS of 48 individuals with variants in MYH7, the gene encoding beta myosin heavy chain, and a personal or family history of cardiomyopathy. The genome sequences were annotated with a custom pipeline optimized for cardiovascular gene variant detection. We utilized multiple lines of evidence to prioritize genes together with rare variant gene-based association testing to identify candidate genetic modifiers.
Results:
GS identified the MYH7 variant in all 48 cases. Several variants were reclassified based on best available data. We identified known disease-associated genes (MYBPC3, FHOD3), a priori candidate modifiers (ATP1A2, RYR2), and novel candidate modifiers of cardiomyopathy including PACSIN3 and SORBS2. We identified regulatory variants and intergenic regions associated with the phenotypes. Using RNA profiling, we show that several genes identified through gene-based association testing are differentially regulated in human hypertrophic cardiomyopathy, and in models of disease.
Conclusion:
Evaluation of the whole genome, even in the case of alleged monogenic disease, leads to important new insights. The identified variants, regions, and genes are candidates to modify disease presentation in cardiomyopathy.
Introduction
Familial cardiomyopathy is a major cause of morbidity and mortality. Hypertrophic cardiomyopathy (HCM) was first mapped by positional cloning to the cardiac beta myosin heavy chain (MYH7) (, ). Subsequently variants in other sarcomeric genes were found to be pathogenic for HCM. Today, a pathogenic genetic variant is identified in <50% of HCM cases (), where rare and private variants in myosin binding protein C (MYBPC3) and MYH7 are most common (). High variability in disease presentation, penetrance and expressivity has caused some to question the single variant nature of these diseases and led to speculation that additional genetic variation may be contributing (–). Disease heterogeneity, both among families with identical “disease-causative” variants and between individuals within these families, can span severity and presentation and complicates diagnosis and prognosis (). Importantly, polygenic risk can explain some variability in disease presentation in patients with HCM (). Additionally, several groups demonstrated that patients harboring multiple rare variants in disease-associated genes may develop severe phenotype or present earlier (–). Genome-wide association studies have identified large effect variants with moderate population frequencies (, ), while small to moderate effect variants and variants of rare frequency that could influence disease heterogeneity have been less well-characterized. Our understanding of how additional genetic variants of intermediate effect, commonly referred to as genetic modifiers, influence the severity and manifestation of causal alleles has been limited, due in part to the difficulties encountered in identifying genetic modifiers. Recent evidence also shows contribution of common variants to the risk of developing HCM (), corroborating its genetic complexity.
Technological advances rapidly reduced the cost of genome sequencing (GS) such that application is a clinical reality. While testing continues to be focused on gene panels for primary variant identification, improved quality of sequencing chemistry and processing algorithms has enabled clinical exome and genome sequencing. GS has identified new pathogenic variants in HCM (), as well as in diseases previously not considered genetic such as acute myocarditis (). Data from gnomAD () have refined our understanding of gene tolerance to variation. We previously explored the concept of gene tolerance and its utility in classifying cardiovascular disease variants (, ). GS uniquely allows interrogation of all genes, regulatory regions, intergenic regions, as well as detection of larger indels and structural variants. In combination with RNA sequencing, the regulatory implications of different variants can be investigated further to improve our understanding of the genetic complexity of disease.
Here, we utilize patient derived GS and multiple sources of transcriptomic data to identify genetic modifiers of the disease phenotype in cardiomyopathy patients with a previously identified variant in MYH7. We develop a pipeline specific to cardiomyopathy, update curation of all putatively causal variants, and examine several aspects of variation uniquely available in genome data. In combination with transcriptional coexpression network data, we identify candidate modifiers of the cardiomyopathy phenotype. The expression profiles of several candidates are assessed in three independent models of cardiac hypertrophy.
Methods
Cohort
The study was approved by local IRB (GAP 4237) and conformed to the Declaration of Helsinki. We identified 48 individuals with prior genetic testing for cardiomyopathy associated variants in MYH7. Patients were recruited from the inherited cardiomyopathy clinics of Stanford University, University of Michigan, and the University of Chicago Medical Centers. Prior to study inclusion, all participants underwent informed consent to research-based genome sequencing. Clinical details including variant classification from the original genetic testing report were obtained. Clinical measurements and demographics are found in Tables 1, 2 and Supplementary Table S1 (echocardiography) and Data S1 (individual clinical characteristics).
Table 1
| HCM | ||||||
|---|---|---|---|---|---|---|
| Trait | N | Median | Mean | SD | Min | Max |
| Age (yrs) | 42 | 49.5 | 47.2 | 16.1 | 7 | 79 |
| Weight (lbs) | 40 | 182.5 | 177.8 | 47.7 | 47 | 272 |
| Height (inches) | 40 | 67 | 66.7 | 5.4 | 48 | 80 |
| Other | ||||||
| Trait | N | Median | Mean | SD | Min | Max |
| Age (yrs) | 6 | 46.0 | 39.3 | 21.2 | 8 | 61 |
| Weight (lbs) | 5 | 143 | 117.8 | 47.8 | 42 | 155 |
| Height (inches) | 5 | 68 | 61.6 | 10.6 | 44 | 69 |
Baseline characteristics.
Table 2
| Name | Level | N | % |
|---|---|---|---|
| Sample origin | Site 1 | 26 | 54 |
| Site 2 | 13 | 27 | |
| Site 3 | 9 | 19 | |
| Sex | F | 24 | 50 |
| M | 24 | 50 | |
| Race | Caucasian | 34 | 71 |
| Hispanic | 2 | 4 | |
| Asian | 3 | 6 | |
| Middle Eastern | 2 | 4 | |
| African American | 7 | 15 | |
| Morphology | Apical hypertrophy | 2 | 4.2 |
| Asymmetric septal hypertrophy | 30 | 62.5 | |
| Burnt-out hypertrophic | 1 | 2.1 | |
| Concentric hypertrophy | 6 | 12.5 | |
| Dilated | 1 | 2.1 | |
| ECG+/LVH- | 3 | 6.2 | |
| Inferior hypertrophy | 2 | 4.2 | |
| Isolated noncompaction | 3 | 6.2 |
Demographics.
Clinical curation
Our curation process was two tiered. First, we manually curated any variant found within MYH7 to confirm the presence of the original diagnosis and reclassified pathogenicity according to additional lines of evidence. Second, we curated a broader set of candidate myocardial genes (n = 452; Supplementary Table S2) to identify alternate pathogenic variants, most of which were not interrogated in the initial gene panel screening. The clinical curation protocol was based on American College of Medical Genetics (ACMG) guidelines (, 19) as described (). The curation classes were: (1) Very likely disease causing (equivalent to “published, disease causing mutation”; “known disease causing mutation”; “pathogenic”; “disease causing mutation”). (2) Likely disease causing (Equivalent to “presumed pathogenic mutation”; “likely pathogenic”; “probably associated”). (3) VUS, likely disease causing (equivalent to “novel variant of uncertain significance, likely disease causing”). (4) VUS (equivalent to “class II possible deleterious mutation”; “VUS”; “novel variant of uncertain significance”). (5) VUS, likely benign. Primary criteria for reclassification included population allele frequency (GnomAD greater than 0.1%), pedigree segregation, supporting publication evidence and clinical laboratory assertions available through ClinVar (March 2021).
Sequencing, variant calling, filtering
Genome sequencing was performed on isolated genomic DNA acquired from blood samples from each participant. DNA library preparation and 2 × 100 paired-end sequencing was completed by Illumina. Coverage was on average 30× and sufficient for high quality germline variant genotyping.
Alignment and variant calling were completed using Real Time Genomics (20). Filtering was applied based on an AVR (adaptive variant rescoring) score of 0.02. Variant imputation, filtering and structural variation calling were performed using a custom pipeline as previously described (21, 22) with modification. Variants were only called at positions that had evidence for an alternate allele. Missing variant imputation was completed to avoid bias during merging samples with different sets of variants. First, the union of variants across all samples was selected. Next, each sample was interrogated for missing genotypes at these positions. Missing genotypes were set to homozygous reference if there was in excess of 10 supporting reads and no evidence of an alternative allele.
The called variants were then limited to those that were novel or had an allele frequency of less than 1% (GnomAD v2 Spring 2021). The adopted 1% minor allele frequency filter is different than what was implemented for pathogenicity as we are considering modifiers of intermediate effect and thus intermediate population frequency. Regions enriched for false positives were also removed (Undiagnosed disease program blacklist (23), ENCODE Mappability (24), Heng Li low complexity (25), GIAB low confidence (26)). To protect against overzealous filtering, variants in ClinVar (Sep 2014), GWAS NHGRI Catalog (Fall 2014) (27), PharmGKB (Fall 2014) (28), Cosmic(v70) (29) were whitelisted. ClinVar variant classifications and disease associations are current as of July 2021 (Supplementary Dataset S1).
The remaining rare high confidence variants were further limited based on functional evidence. Specifically, variants were selected that were predicted by snpEff (30) to have moderate to high impact on protein function or have a normalized CADD score (31) greater than 20. The resulting VCF was subdivided into three sets depending on the required analysis. Set 1 includes all functional candidate variants, both genic and intergenic. Set 2 includes the genic region (refFlat Fall 2014) including introns and 5 kb up and downstream of the transcription start site. Set 3 is a digital exome using a 10 bp extension of the Agilent SureSelect exome capture v2. Each of these sets was selected for burden testing in order to compare power of discovery for a gene agnostic sliding window, whole gene region and coding exome.
We used a custom pipeline to call structural variants (SVs) across the genome. As structural variant callers are known to have lower confidence particularly with short read sequences, we evaluated for SVs that were shared among multiple algorithms and restricted to no more than 20% of samples. The tools included—breakdancer v1.1.2 (32), breakseqlite v1.0, cnvnator v0.2.7 (33), delly v0.0.9 (34) and freec v1.0 (35). High confidence copy number calls are reported in the analysis. They include anything called by Breakseqlite (36) (which is considered conservative) or having greater than 50% reciprocal overlap between at least two algorithms.
Intergenic and pathway burden testing
Intergenic regions were tested through a 50 kb sliding window with 25 kb overlap (∼5 variants). Pathways were based primarily on candidates gene sets of mitochondrial and sarcomeric function. Additionally, a large number gene sets from Reactome (37) and MsigDB (38) were used for exploratory hypothesis generation. A key challenge with burden testing is appropriate selection, tuning of the number of variants (or genes) and subsequent weighting. The default, internally calculated, frequency based weighting parameters were used with SKAT.
Aggressive post burden test filtering was applied to the case control analysis to protect against false positives due to platform bias (genome vs. exome sequencing). Genes were removed if they were previously implicated as spurious in the UDP (23) or had a prefix consistent with large paralogous gene families (OR, PRAME, MUC, POTE, BAGE, ANK, NBF, DNA, DYN, CCDC, PCD, DUX, D3X, KRT, FOX, PRSS, KIR, OPN, USP). Preliminary analysis indicated comparison of genome to exome sequencing results in spurious batch effects enriched for gene families due to capture specificity or lack thereof. Burden testing results are available in Supplementary Data S4.
Statistical analysis
All analysis was completed using the R statistical environment and Bioconductor (39). Burden testing was performed using SKAT with adaptive weighting and adjustment for small sample sizes (40). In addition, for each region Fisher exact tests were used to compare the number of samples with rare variants among high and low groups. The high group was defined by median dichotomization for continuous traits or cases with binary trait analysis. The frequency of observed rare functional alleles was reported for each group (including a proportion test) to estimate the direction and magnitude of burden effect.
Burden testing was applied to four traits: maximum left ventricular wall thickness (LVWT), ejection fraction (EF), left ventricular outflow tract gradient (LVOTG) and case control status. The first three traits were analyzed within the cohort while case control analysis compared HCM patients against external controls (ARIC, n = 100) (41). For within cohort analysis a multivariate model using age, sex and BMI was used for adjustment with SKAT.
Modifier gene prioritization
Modifier identification was performed using a gene-ranking algorithm based on a custom point system rewarding different analytical and annotation lines of evidence (Table 3). Gene-based association testing using both SKAT and SKAT-O was applied to four traits: maximum LVWT, EF, LVOTG and case control status. All gene-based association testing was restricted to unrelated Caucasian patients with clinically diagnosed HCM (N = 28). For within cohort analysis a multivariate model using age, sex and BMI was used for adjustment. The modifier algorithm also incorporated extensive myocardial gene expression data from heart failure and hypertrophy (42), GnomAD missense and loss of function scores, cardiac gene expression level, as well as the curated candidate myocardial gene list (Supplementary Table S2). The primary analysis was LVWT and therefore any gene reaching a nominal burden testing p-value < 0.05 was assigned 2 points. EF, LVOTG and Case-Control were secondary analyses and assigned 1 point each. The lowest burden test p-value for LVWT, EF, LVOTG and Case-Control per gene was used in the modifier scoring algorithm. Heart gene expression and significant differential expression within hypertrophy or heart failure coexpression networks (42) were each assigned 1 point. RNA expression was assessed based on the mean RPKM (reads per kilobase of exon per million reads mapped) values for 82 left ventricle GTEx (43) samples (>10 RPKM gave 1 point). GnomAD loss of function (LOF) z-score >3 and missense z-score >3 (positive z-scores indicate fewer variants than expected) each gave 1 point. Candidate genes (Supplementary Table S2), manually curated by a group of cardiologists specializing in inherited cardiovascular disease, were given 2 points. Genes previously flagged as prone to false positive signals (23) lost 2 points.
Table 3
| Trait | Criteria | Points |
|---|---|---|
| Left Ventricular Wall Thickness (LVWT) | Gene-based ass. test p < 0.05 | 2 |
| Ejection Fraction (EF) | Gene-based ass test p < 0.05 | 1 |
| Maximal Left Ventricular Outflow Tract Gradient (LVOTG) | Gene-based ass test p < 0.05 | 1 |
| Case Control ARIC (WES, N = 100), (Fu et al., 2013) | Gene-based ass test p < 0.05 | 1 |
| GTEx Gene Expression | Cardiac RPKM > 10 | 1 |
| GnomAD LOF | >3 SD | 1 |
| GnomAD MIS tolerance | >3 SD | 1 |
| Hypertrophy vs. Normal (coexpression networks) | Q < 0.01 | 1 |
| Heart Failure vs. Normal (coexpression networks) | Q < 0.01 | 1 |
| Candidate Cardiac Gene | N = 452 genes | 2 |
| Flagged Prefix or UDP Blacklist | −2 |
Modifier gene scoring algorithm.
Human HCM validation
Cardiac gene expression of selected top candidate modifiers were investigated in a separate cohort of 39 HCM patients and 13 healthy control individuals (IRB approval GAP 4237). The HCM cohort (excluding one individual without available data) was 34% female and composed of individuals with a mean age of 57.9 years (standard deviation, SD = 15.7), mean height of 169.6 cm (SD = 12.8) and mean weight of 86.7 kg (SD = 34.0). RNA was isolated from cardiac left ventricle tissue from cardiac transplants or myectomies using the mirVana miRNA isolation kit (ThermoFisher Scientific) according to the manufacturer's specifications. Total RNA was reverse transcribed to cDNA using the High-Capacity cDNA Reverse Transcription kit (ThermoFisher Scientific). Quantitative real-time PCR was performed on a ViiA 7 Real-Time PCR System (ThermoFisher Scientific) using pre-designed Taqman gene expression assays from ThermoFisher Scientific (FHOD3 Hs00400902_m1, MSRB2 Hs00255292_m1, MYH7B Hs00293096_m1, PACSIN3 Hs00367625_m1, SORBS2 Hs01125197_m1) or predesigned probes from IDT (NPPB HS.PT.58.19450190). The eukaryotic elongation factor EEF1 (IDT predesigned probe Hs.PT.58.3514123) was used as a housekeeping gene, and expression was quantified using the ΔΔCT method followed by an unpaired t-test with BH-correction.
Functional RNA-seq verification
All animal procedures were in keeping with all federal and state regulations governing the humane care and use of laboratory animals, including the USDA Animal Welfare Act, and our Assurance of Compliance with PHS Policy on Humane Care and Use of Laboratory Animals, Animal Welfare Assurance Number: A3213-01, in accordance with the NIH Guide for the Care and Use of Laboratory Animals. The laboratory animal care program at Stanford is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC International, Accredited Unit Number 000679). All animals were handled under protocols 22920 and 22922 approved by the Stanford Administrative Panel on Laboratory Animal Care. Mice were anesthetized with 3% isofluorane (inhalation), euthanized using cervical dislocation, after which the hearts were removed. The methods used to generate and analyze cardiac RNA sequencing data from the MYL2 transgenic mouse model have been described in detail elsewhere (44).
Neonatal rats were anesthetized on a pad on ice for 20 min and euthanized by decapitation. Neonatal rat ventricular myocytes (NRVMs) were isolated using standard methods on postpartum day 3 using the Worthington Neonatal Cardiomyocytes isolation system. After removal of non-cardiomyocyte cells, myocytes were plated on collagen I coated plates in DMEM 7.5% FBS, 7.5% horse serum, and penicillin/streptomycin. Forty-eight hours after isolation, cells were treated with 50 uM phenylephrine in low glucose DMEM with ITS and 20 mM AraC. Phenylephrine treatment (2–50uM) for 24–48 h is known to induce cardiomyocyte hypertrophy (increased cell volume, cell area and total protein content) (45–48). A subset of cells were harvested prior to addition of phenylephrine; half of remaining wells were treated with media alone. After 24 h and 48 h of treatment, acute phenylephrine induced cardiac cells were harvested. RNA was extracted using the Qiagen RNeasy kit according to the manufacturer's instructions and was DNase-treated using the DNA-free RNA kit from Zymo Research. RNA integrity was verified using a 2100 BioAnalyzer (Agilent) and all samples had an RIN score of 7.0 or higher. RNAseq libraries were prepared using the TrueSeq Stranded mRNA kit (Illumina), according to the manufacturers' instructions. Libraries were barcoded, quality-checked and run in rapid run flow cells in a HiSeq 2,500 (Illumina), producing at least 30 million paired-end reads. Sequencing reads were aligned to the Rattus Norvegicus rn5 UCSC reference genome using the STAR (49) and Cufflinks was used to quantify and perform differential expression (50). Reads were normalized using Cufflinks and FPKM (Fragments Per Kilobase Of Exon Per Million Fragments Mapped) was calculated on a per gene basis. We evaluated the FPKM count for top candidate modifiers and canonical markers of the acute hypertrophic program and evaluated the differential expression after phenylephrine vs. pre-treatment as a ratio vs. sham vs. pretreatment. All genes with an FPKM>1 were considered expressed and included in the analysis.
Results
Genome sequencing of patients harboring MYH7 variants
Patients were classified based on cardiac morphology and MYH7 variant identified (primary variants identified between 2007 and 2011, n = 33, Tables 1-2, Supplementary Table S1 and Supplementary Data S1). Of the 48 patients (7 to 79 years old), 50% were female. The cohort included 6 families for a total of 40 unrelated individuals. Cardiomyopathy phenotypes were classified as hypertrophic in 42, dilated without known prior hypertrophy in 1, and noncompaction in 3. The overall study design is illustrated in Figure 1.
Figure 1
Multiple genetic variants of different classifications in MYH7 have been reported in GnomAD () and ClinVar (51) (Figure 2A). Using our automated genome annotation pipeline, we re-identified all unique MYH7 variants detected on initial panel-based sequencing (population minor allele frequency <0.1%, Figure 2B bottom panels, Supplementary Dataset S1). They were distributed across the actin-binding domain and the rod region, similar to the majority of reported variants in ClinVar (Figure 2B, top panels). All MYH7 variants reported on prior clinical testing were identified and called at high quality and adequate depth to confidently call heterozygosity. All other genomic variants identified on panel testing were confirmed.
Figure 2
MYH7 variant reclassification
Secondary findings—coding
We next searched for secondary likely pathogenic genetic variants that may contribute to the cardiomyopathy phenotype (Supplementary Data S2). In addition to potentially disease-associated variants in MYH7 from panel based testing, we identified one MYBPC3 VUS (p.Val757Met), and rare PRKAG2 variants (p.Val535Gly and p.Val534Gly respectively). We identified an early termination (p. Cys1013X) and rare missense (p.Lys953Gln) variant in FLNC, a gene first implicated in hypertrophic and dilated cardiomyopathy (DCM) years after the patients' clinical tests were reported (52, 53). Interestingly, the former FLNC truncation variant was found in a patient with a family history of DCM whose MYH7 variant was reclassified to benign. Another patient whose MYH7 variant was initially classified as VUS also had a rare nonsynonymous variant in RNA binding motif protein 20 (RBM20 p.Ile921Val), a titin-splicing gene implicated in cardiomyopathy (54). Two rare variants in BCL2-associated athanogene-3 (BAG3 p.Glu471Gly and p.Arg473Gly), a stress responsive protein implicated in familial DCM were also identified (55–57). The MYH7 Variant Reclassification is summarized in Supplementary Figure S1.
Review of rare coding variants in a cardiovascular subset of the 78 ACMG gene list (58) identified additional rare variants (Supplementary Data S2). These were found in genes associated with arrhythmogenic right ventricular cardiomyopathy (DSC2, DSG2, TMEM43, PKP2, DSP); Catecholaminergic polymorphic ventricular tachycardia (RYR2, CASQ2, TRDN); DCM (LMNA, FLNC, TTN, BAG3, RBM20); Vascular Ehlers-Danlos Syndrome (COL3A1); Long QT Syndrome 3/Brugada Syndrome (SCN5A); Familial Hypercholesterolemia (LDLR, APOB) and aortopathies (TGFBR1, SMAD3, MYH11).
Secondary findings—non-coding
Next, we interrogated miRNA binding sites and consensus promoter regions for potentially interesting variants (Supplementary Data S3). We identified two variants in conserved miRNA binding sites of genes previously implicated in cardiomyopathy: SCN5A (chr3:38589677) and RAF1 (chr3:12625903). The RAF1 miRNA binding site variant alters position 5 of a consensus seed recognition sequence. This variant is predicted to disrupt a permissive consensus binding site recognized by multiple miRNAs and found in more than 290 genes. We also identified a variant in a miRNA binding site of ACTN2 (chr1:236927207), a gene for which we and others recently demonstrated that protein-truncating variants cause hypertrophy and restrictive cardiomyopathy (RCM) in humans (59). We found variants of uncertain significance in non-coding RNA, promoter, UTR, enhancers and nonsynonymous variants in alternative isoforms of tropomyosin found in long-read heart RNAseq data (Supplementary Table S3). Published work demonstrates a protective role of long non coding RNAs (mhrt) that reside in the 3' myosin tail-coding domain and downstream of MYH7 (60). We identified 5 rare nonsynonymous variants that intersect with exons of these transcripts (Supplementary Data S3 and Table S3). As these variants affect both coding and non-coding transcripts, the impact of these variants is currently unknown. Reclassification (61) of these variants without knowledge of the role of their impact on Mhrt transcripts resulted in downgraded pathogenicity.
Scoring algorithm for modifier identification
We developed a multi-omic cardiomyopathy-data rich metric of modifying potential to evaluate for genetic modifiers of the HCM phenotype. To prioritize genes, we developed a 12-point scale (Table 3; Methods) that combined rare variant gene-based association testing with multiple external priors, including extensive myocardial gene expression data from heart failure and hypertrophy. Inclusion of parameters such as LVWT and disease-specific gene expression data enhanced sensitivity to an HCM-specific phenotype and cardiac function. There were 165 genes that reached a modifier score of 6 or better (Supplementary Table S4, see Supplementary Data S4 for full table) and 51 genes had scores ≥7. CACNA1C scored 10, while RYR2, TTN, ATP1A2, FHOD3, TJP2, CACNA1D and DYNC1H1 had modifier scores of 9. Several were identified as a priori candidates. The sodium-potassium ATPase subunit alpha 2 gene (ATP1A2) was highly significant in the case-control comparison (p < 4 × 10−19). The cardiac specific ryanodine receptor encoded by RYR2 was associated with increased wall thickness (p < 0.01), a trend towards LVOT gradient (p = 0.07) and with HCM in the case-control comparison (p < 0.05). Several variants in the L-type calcium channel component CACNA1C have also been demonstrated to predispose for arrhythmic phenotypes, especially long-QT syndromes (62), while the gap junction protein encoded by TJP2 has been associated with hypertrophy in other cell types (63).
Validating our approach, the known modifier Formin homology 2 domain containing 3 (FHOD3) was a top scoring modifier. FHOD3 has been implicated as disease predisposing in DCM and HCM (64, 65) and as an HCM modifier in case-control common variant analysis and a genome-wide association study (, 66). Previously cited high frequency variants (rs516514, rs2303510) were not included in the rare functional variants used for gene-based association testing; despite this, variation in FHOD3 was associated with increased LVWT (p < 0.05). SORBS2 (sorbin and SH3 domain-containing 2), modifier score 6, is an adhesion junction protein that was recently associated with arrhythmogenic cardiomyopathy (ACM). Knockdown of SORBS2 in mice resulted in an ACM-like phenotype and two patients with ACM have been identified to carry likely pathogenic variants in SORBS2 (67).
We identified several genes as novel candidate modifiers of the HCM phenotype (Supplementary Table S4). Rare variant gene-based association testing of DYNC1H1 (score 9), the heavy chain component of dynein, was associated with increased LVWT (p < 0.01) and reduced EF (p < 0.01). Another top modifier, HNRNPC (score 8), was recently identified as a regulator of sarcomeric protein translation with higher expression in failing hearts (68). ERBB2 (score 8) and ERBB4 (score 7), both Neuregulin-1 receptors, are involved in cardiac regeneration after injury (69, 70), and Neuregulin-1 itself is a therapeutic target for heart failure (71). Rare variants in CAMSAP1 (score 7) were found in 8 participants with severely increased LVWT but not in participants with milder hypertrophy (p < 0.001). ASH1l (score 7), a histone H3 methyltransferase, was most significant in the case-control comparison (p < 1 × 10−35). The transcription cofactor LIM domain binding 2 (LDB2, score 6) was associated with LVWT (p < 0.01) and with case status in case-control analysis (p < 2 × 10−15). PACSIN3 (score 6) is an adapter protein that regulates membrane dynamics. Cardiomyocytes in PACSIN3 knockout mice lack caveolae (72), while its potential modifying function in cardiac hypertrophy remains to be elucidated.
Independent experimental RNA profiling of identified candidate modifiers
To further evaluate if the identified candidate modifier genes were involved in cardiac hypertrophy, we analyzed RNA sequencing data from a mouse model of RCM and a cellular model of acute hypertrophy in neonatal rat ventricular myocytes (NRVMs). We specifically investigated the relative change in expression for all modifier genes with a score of 6 or above (n = 165) in response to the chronic and acute hypertrophic stimulus (n = 106 detected in both, Figures 3A,B, Supplementary Table S5, with low-scoring genes shown in Supplementary Figure S2A). While a change in expression suggests a role in development of cardiac hypertrophy, lack of change does not invalidate a potential modifier. We confirmed several genes as highly potentiated by a hypertrophic signal, including the known modifier FHOD3, and UCHL1 (Supplementary Figure S2B), for which knockdown in cardiomyocytes was recently shown to prevent hypertrophy (73). In contrast, other modifiers were modestly changed or expressed at low levels in cardiomyocytes, such as CAMSAP1 and ASH1l. The most downregulated modifier in response to both acute and long-term hypertrophy was the potassium channel gene KCNJ3 (score 7, Supplementary Figure S2C). Genetic variation in KCNJ3 is associated with arrhythmias, and blocking the channel in zebrafish improved the arrhythmogenic phenotype (74).
Figure 3
Next, we analyzed gene expression differences in human left ventricular myocardial tissue from an independent cohort of 39 HCM patients compared to healthy controls (N = 13). Expression of the hypertrophy marker NPPB and five candidate modifiers (FHOD3, MSRB2, MYH7B, PACSIN3 and SORBS2) in all three experiments are shown in Figure 3C. The expression changes in SORBS2 follows the effect of NPPB, suggesting a role in hypertrophic remodeling. To further explore the utility of gene expression data in identifying and explaining the roles of modifiers, we assessed the expression of genes with recently-identified HCM susceptibility loci (, ) in our cardiomyopathy models. Genes with known cardiac functions, including BAG3, PLN, TBX3, TRDN, and MTSS1, all had lower expression in both the acute and chronic cardiomyopathy compared to controls (Supplementary Figure S3). SLC6A6, a taurine transporter, was higher in both models. ADPRHL1, a gene implicated in cardiac development, was upregulated in response to acute hypertrophy and downregulated in the chronic hypertrophy model (Supplementary Figure S3, Table S5).
Discussion
Genome sequencing offers unique and untapped power for understanding the complexity of genetic disease. Variability in severity, penetrance, and phenotype found within and among families harboring putatively disease-causative MYH7 variants is presumed to be caused by both genetic and environmental modifiers. We evaluated the utility of GS in combination with cardiac expression data to identify candidate genetic modifiers in a patient cohort initially diagnosed with monogenic cardiomyopathy attributed to variants in MYH7.
Whereas prior studies of GS in HCM have focused on its utility in providing a genetic diagnosis in cardiomyopathy (, 75), we showed how comprehensive data from GS of genetically diagnosed HCM patients identified potential genetic modifiers of the phenotype. Increasing evidence suggests that HCM is not a wholly monogenic disease. We searched each genome for evidence of additional rare variants causative of or substantially contributory to the observed cardiomyopathy phenotype and found rare protein altering variants in multiple genes and individuals, including an early termination variant in the cardiomyopathy associated gene FLNC. A VUS in FLNC in the presence of a VUS in MYBPC3 has previously been suggested as a potential modifier of HCM (75). These findings support previously identified advantages of GS in HCM, including the potential to improve yield in testing for primary pathogenic variants (), and identify a range of secondary findings throughout the genome (75). Further exploration of secondary genetic variants, where gene expression is one potential tool, is necessary to validate their significance in disease pathophysiology and translate such findings into clinically actionable insight.
Novel potential genetic contributors to disease were discovered in the non-coding genome, including microRNA sites and lncRNAs. The discovery of non-coding DNA variants that may act as disease modifiers is the first step in developing a new field of biology aimed at understanding how regulatory gene variants impact Mendelian disease; this is fodder for applied genetic research. Further mechanistic research is needed to understand the impact of non-coding variants in the genetic basis for HCM.
We further explored the genomes for modifiers of disease phenotype. With limited sample size to afford true statistical power for genome wide testing we undertook two strategies to maximize the robustness of findings. We used a gene scoring algorithm that boosted nominally significant modifier phenotype associations with specialized annotation of hypertrophic cardiomyopathy and heart failure molecular phenotypes. We prioritized variants based on cardiac expression and differential expression in cardiac hypertrophy and heart failure. Several candidates were investigated for cardiac expression changes in a separate cohort of human HCM, a transgenic mouse model of chronic hypertrophy and an acute hypertrophy model in NRVMs. Our top candidates included previously known modifier genes (FHOD3), a gene known to cause DCM and HCM when mutated (TTN) and genes associated with related cardiovascular phenotypes such as heart failure (HNRNPC) and arrhythmia (CACNA1C, RYR2). The plausibility, and in the case of for example FHOD3, SORBS2 and UCHL1, replication of prior published results, lends credibility to our method and strengthen the discovery of novel candidates such as CAMSAP1, MYH7B and PACSIN3. Importantly, rare genetic variation does not inform directionality of effects, and utilizing several disease models for investigation of potential modifier expression changes in response to acute or chronic hypertrophy emphasizes the complexity of the observed effects. For FHOD3, for example, expression was substantially lower in RCM mice, but showed a trend towards higher levels in the HCM validation cohort and in response to acute hypertrophy.
Our study has several limitations. Our sample size is limited and includes mostly Caucasian individuals. The modifier scoring algorithm was developed to include cardiomyopathy-relevant metrics, but is limited by its scope and selection of scoring cutoff. While we further evaluated some of the modifiers using cardiac hypertrophy models and a separate HCM cohort, larger cohort studies are needed to examine their potential clinical relevance and future mechanistic studies to establish causal evidence. Importantly, the cell and animal models are limited with regards to cross-species concordance and the potential impact by acute or chronic hypertrophy at two time points. They are therefore unlikely to capture all differential signaling that influence human HCM development over time. Lack of validation thus does not invalidate a putative modifier. In addition, identified phenotypic associations were concurrent with the point of assessment. Hence, the phenotypic association is contingent upon the gene's direct impact but also on potential gene-mediated influences on ascertainment timing, treatment history etc. The test statistics and p-values will be inflated/deflated due to multiple tests using sparse data and should therefore only be used for ranking purposes and not to determine actual statistical significance. Furthermore, no validation was performed at the protein level, which will be an important avenue for future research as proteomic and phosphoproteomic signatures also impact disease severity in sarcomeric HCM (76, 77).
In summary, our results provide new insights into genetic modifiers of HCM, including disease-associated genes, proximal regulatory regions and non-coding variants. The complexity of secondary genetic variants with respect to modifying effects is currently minimally evaluated. The initial cataloging of these gene-gene interactions are preliminary and will require refinement and extension, just as the initial discovery of causal MYH7 variants have been. We hypothesize that these secondary findings provide greater understanding in the interpretation of primary variants, and could eventually provide utility in predicting disease severity. True modifiers of disease severity represent promising targets for drug therapy irrespective of causative variants and warrant further mechanistic investigation.
Statements
Data availability statement
The genome data presented in the current publication have been deposited in and are available from the dbGaP database under dbGaP Study Accession phs004024.v1.p1.
Ethics statement
The studies involving humans were approved by Stanford University Institutional Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. The animal study was approved by Laboratory Animal Care (APLAC) at Stanford University. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
ML: Formal analysis, Visualization, Writing – original draft, Writing – review & editing. SA: Formal analysis, Visualization, Writing – review & editing. DW: Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. MG: Data curation, Writing – review & editing. FD: Methodology, Writing – review & editing. CP: Formal analysis, Writing – review & editing. AP: Data curation, Project administration, Writing – review & editing. CS: Investigation, Writing – review & editing. YH: Investigation, Writing – review & editing. LB: Formal analysis, Writing – review & editing. RG: Formal analysis, Writing – review & editing. PC: Methodology, Writing – review & editing. AE: Data curation, Writing – review & editing. JP: Methodology, Writing – review & editing. HC: Data curation, Writing – review & editing. MP: Conceptualization, Investigation, Writing – review & editing. SD: Conceptualization, Investigation, Writing – review & editing. EM: Conceptualization, Investigation, Writing – review & editing. TC: Conceptualization, Investigation, Writing – review & editing. GD: Conceptualization, Investigation, Writing – review & editing. EA: Conceptualization, Funding acquisition, Investigation, Project administration, Supervision, Writing – review & editing. MW: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. Parts of this work were supported by NIH grants R01 HL108943 (GWDII), R01 HL128075 (EMM), T32 HL094274 (FED, AE), K12 HD000850 (JRP), U01 HG007708 (MTW, EAA), the Knut and Alice Wallenberg Foundation (MEL), Graciano Family Fund (MW), and unrestricted grants from the Li Ka-shing Foundation, Breetwor Foundation, and SP (DW, AP, EA).
Acknowledgments
We thank the subjects for their participation.
Conflict of interest
EA is a founder of Personalis, Inc, DeepCell, Inc, Svexa Inc., a founding advisor of Nuevocor, a non-executive director at AstraZeneca, an advisor to SequenceBio, Novartis, Medical Excellence Capital and Foresite Capital. MW, PC, FD hold equity in Personalis. MW has past and current clinical research support from Novartis, Cytokinetics, BMS, Alexion, and Salubris Bio and has been a consultant to BMS and Cytokinetics. Current company employees; DW -Svexa; RG -AstraZeneca; PC -Stripe; JP -Tenaya Therapeutics; AE -ZS; FD -Versant Ventures. EMM has been a consultant to Amgen, AstraZeneca, Avidity, Cytokinetics, PepGen, Pfizer and Tenaya Therapeutics, and is founder of Ikaika Therapeutics and Kardigan Therapeutics.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546493/full#supplementary-material
References
1.
JarchoJAMcKennaWPareJASolomonSDHolcombeRFDickieSet alMapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. (1989) 321:1372–8. 10.1056/NEJM198911163212005
2.
Geisterfer-LowranceAAKassSTanigawaGVosbergHPMcKennaWSeidmanCEet alA molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. (1990) 62:999–1006. 10.1016/0092-8674(90)90274-I
3.
WalshRMazzarottoFWhiffinNBuchanRMidwinterWWilkAet alQuantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Med. (2019) 11:5. 10.1186/s13073-019-0616-z
4.
MaronBJMaronMS. Hypertrophic cardiomyopathy. Lancet. (2013) 381:242–55. 10.1016/S0140-6736(12)60397-3
5.
LopesLRZekavatiASyrrisPHubankMGiambartolomeiCDalageorgouCet alGenetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet. (2013) 50:228–39. 10.1136/jmedgenet-2012-101270
6.
HarperARParikhVNGoldfederRLCaleshuCAshleyEA. Delivering clinical grade sequencing and genetic test interpretation for cardiovascular medicine. Circ Cardiovasc Genet. (2017) 10(2):e001221. 10.1161/CIRCGENETICS.116.001221
7.
WatkinsHAshrafianHRedwoodC. Inherited cardiomyopathies. N Engl J Med. (2011) 364:1643–56. 10.1056/NEJMra0902923
8.
TadrosRFrancisCXuXVermeerAMCHarperARHuurmanRet alShared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. (2021) 53(2):128–34. 10.1038/s41588-020-00762-2
9.
MaronBJMaronMSSemsarianC. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm. (2012) 9:57–63. 10.1016/j.hrthm.2011.08.009
10.
GirolamiFHoCYSemsarianCBaldiMWillMLBaldiniKet alClinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. (2010) 55:1444–53. 10.1016/j.jacc.2009.11.062
11.
ZouYWangJLiuXWangYChenYSunKet alMultiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy. Mol Biol Rep. (2013) 40:3969–76. 10.1007/s11033-012-2474-2
12.
HarperARGoelAGraceCThomsonKLPetersenSEXuXet alCommon genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. (2021) 53(2):135–42. 10.1038/s41588-020-00764-0
13.
BagnallRDInglesJDingerMECowleyMJRossSBMinocheAEet alWhole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. (2018) 72:419–29. 10.1016/j.jacc.2018.04.078
14.
KontorovichARPatelNMoscatiARichterFPeterIPurevjavEet alMyopathic cardiac genotypes increase risk for myocarditis. JACC Basic Transl Sci. (2021) 6:584–92. 10.1016/j.jacbts.2021.06.001
15.
KarczewskiKJFrancioliLCTiaoGCummingsBBAlföldiJWangQet alThe mutational constraint spectrum quantified from variation in 141,456 humans. Nature. (2020) 581:434–43. 10.1038/s41586-020-2308-7
16.
PanSCaleshuCADunnKEFotiMJMoranMKSoyinkaOet alCardiac structural and sarcomere genes associated with cardiomyopathy exhibit marked intolerance of genetic variation. Circ Cardiovasc Genet. (2012) 5:602–10. 10.1161/CIRCGENETICS.112.963421
17.
GolbusJRPuckelwartzMJFahrenbachJPDellefave-CastilloLMWolfgeherDMcNallyEM. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet. (2012) 5:391–9. 10.1161/CIRCGENETICS.112.962928
18.
RichardsCSBaleSBellissimoDBDasSGrodyWWHegdeMRet alACMG Recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. (2008) 10:294–300. 10.1097/GIM.0b013e31816b5cae
19.
RichardsSAzizNBaleSBickDDasSGastier-FosterJet alStandards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. (2015) 17:405–24. 10.1038/gim.2015.30
20.
ClearyJGBraithwaiteRGaastraKHilbushBSInglisSIrvineSAet alJoint variant and de novo mutation identification on pedigrees from high-throughput sequencing data. J Comput Biol. (2014) 21:405–19. 10.1089/cmb.2014.0029
21.
PriestJRGawadCKahligKMYuJKO’HaraTBoylePMet alEarly somatic mosaicism is a rare cause of long-QT syndrome. Proc Natl Acad Sci U S A. (2016) 113:11555–60. 10.1073/pnas.1607187113
22.
PriestJROsoegawaKMohammedNNandaVKunduRSchultzKet alde novo and rare variants at multiple loci support the oligogenic origins of atrioventricular septal heart defects. PLoS Genet. (2016) 12:e1005963. 10.1371/journal.pgen.1005963
23.
Fuentes FajardoKVAdamsD, NISC Comparative Sequencing Program, MasonCESincanMTifftCet alDetecting false-positive signals in exome sequencing. Hum Mutat. (2012) 33:609–13. 10.1002/humu.22033
24.
ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. (2012) 489:57–74. 10.1038/nature11247
25.
LiH. Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics. (2014) 30:2843–51. 10.1093/bioinformatics/btu356
26.
ZookJMChapmanBWangJMittelmanDHofmannOHideWet alIntegrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol. (2014) 32:246–51. 10.1038/nbt.2835
27.
WelterDMacArthurJMoralesJBurdettTHallPJunkinsHet alThe NHGRI GWAS catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. (2014) 42:D1001–6. 10.1093/nar/gkt1229
28.
Whirl-CarrilloMMcDonaghEMHebertJMGongLSangkuhlKThornCFet alPharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. (2012) 92:414–7. 10.1038/clpt.2012.96
29.
ForbesSABhamraGBamfordSDawsonEKokCClementsJet alThe catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet. (2008). Chapter 10:Unit 10.1157(1):10.11.1-26. 10.1002/0471142905.hg1011s57
30.
CingolaniPPlattsAWangLLCoonMNguyenTWangLet alA program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). (2012) 6:80–92. 10.4161/fly.19695
31.
KircherMWittenDMJainPO’RoakBJCooperGMShendureJ. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. (2014) 46:310–5. 10.1038/ng.2892
32.
FanXAbbottTELarsonDChenK. Breakdancer: identification of genomic structural variation from paired-end read mapping. Curr Protoc Bioinformatics. (2014) 45:15.6.1–11. 10.1002/0471250953.bi1506s45
33.
AbyzovAUrbanAESnyderMGersteinM. CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. Genome Res. (2011) 21:974–84. 10.1101/gr.114876.110
34.
RauschTZichnerTSchlattlAStützAMBenesVKorbelJO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. (2012) 28:i333–9. 10.1093/bioinformatics/bts378
35.
BoevaVPopovaTBleakleyKChichePCappoJSchleiermacherGet alControl-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. (2012) 28:423–5. 10.1093/bioinformatics/btr670
36.
LamHYKMuXJStützAMTanzerACaytingPDSnyderMet alNucleotide-resolution analysis of structural variants using BreakSeq and a breakpoint library. Nat Biotechnol. (2010) 28:47–55. 10.1038/nbt.1600
37.
JassalBMatthewsLViteriGGongCLorentePFabregatAet alThe reactome pathway knowledgebase. Nucleic Acids Res. (2019) 48:D498–503. 10.1093/nar/gkz1031
38.
SubramanianATamayoPMoothaVKMukherjeeSEbertBLGilletteMAet alGene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. (2005) 102:15545–50. 10.1073/pnas.0506580102
39.
GentlemanRCCareyVJBatesDMBolstadBDettlingMDudoitSet alBioconductor: open software development for computational biology and bioinformatics. Genome Biol. (2004) 5:R80. 10.1186/gb-2004-5-10-r80
40.
LeeSEmondMJBamshadMJBarnesKCRiederMJNickersonDAet alOptimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet. (2012) 91:224–37. 10.1016/j.ajhg.2012.06.007
41.
FuWO’ConnorTDJunGKangHMAbecasisGLealSMet alAnalysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. (2013) 493:216–20. 10.1038/nature11690
42.
DeweyFEPerezMVWheelerMTWattCSpinJLangfelderPet alGene coexpression network topology of cardiac development, hypertrophy, and failure. Circ Cardiovasc Genet. (2011) 4:26–35. 10.1161/CIRCGENETICS.110.941757
43.
GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet. (2013) 45:580–5. 10.1038/ng.2653
44.
Zaleta-RiveraKDainisARibeiroAJSCorderoPRubioGShangCet alAllele-specific silencing ameliorates restrictive cardiomyopathy attributable to a human myosin regulatory light chain mutation. Circulation. (2019) 140:765–78. 10.1161/CIRCULATIONAHA.118.036965
45.
SimpsonP. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest. (1983) 72:732–8. 10.1172/JCI111023
46.
EbleDMQiMWaldschmidtSLucchesiPAByronKLSamarelAM. Contractile activity is required for sarcomeric assembly in phenylephrine-induced cardiac myocyte hypertrophy. Am J Physiol Cell Physiol. (1998) 274:C1226–37. 10.1152/ajpcell.1998.274.5.C1226
47.
LinY-HWarrenCMLiJMcKinseyTARussellB. Myofibril growth during cardiac hypertrophy is regulated through dual phosphorylation and acetylation of the actin capping protein CapZ. Cell Signal. (2016) 28:1015–24. 10.1016/j.cellsig.2016.05.011
48.
HartmanTJMartinJLSolaroRJSamarelAMRussellB. Capz dynamics are altered by endothelin-1 and phenylephrine via PIP2- and PKC-dependent mechanisms. Am J Physiol Cell Physiol. (2009) 296:C1034–9. 10.1152/ajpcell.00544.2008
49.
DobinADavisCASchlesingerFDrenkowJZaleskiCJhaSet alSTAR: ultrafast universal RNA-seq aligner. Bioinformatics. (2013) 29:15–21. 10.1093/bioinformatics/bts635
50.
TrapnellCRobertsAGoffLPerteaGKimDKelleyDRet alDifferential gene and transcript expression analysis of RNA-seq experiments with TopHat and cufflinks. Nat Protoc. (2012) 7:562–78. 10.1038/nprot.2012.016
51.
LandrumMJChitipirallaSBrownGRChenCGuBHartJet alClinvar: improvements to accessing data. Nucleic Acids Res. (2020) 48:D835–44. 10.1093/nar/gkz972
52.
Valdés-MasRGutiérrez-FernándezAGómezJCotoEAstudilloAPuenteDAet alMutations in filamin C cause a new form of familial hypertrophic cardiomyopathy. Nat Commun. (2014) 5:5326. 10.1038/ncomms6326
53.
DeoRCMussoGTasanMTangPPoonAYuanCet alPrioritizing causal disease genes using unbiased genomic features. Genome Biol. (2014) 15:534. 10.1186/s13059-014-0534-8
54.
GuoWSchaferSGreaserMLRadkeMHLissMGovindarajanTet alRBM20, A gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med. (2012) 18:766–73. 10.1038/nm.2693
55.
SchoenauerRLangeSHirschyAEhlerEPerriardJ-CAgarkovaI. Myomesin 3, a novel structural component of the M-band in striated muscle. J Mol Biol. (2008) 376:338–51. 10.1016/j.jmb.2007.11.048
56.
BrauchKMKarstMLHerronKJde AndradeMPellikkaPARodehefferRJet alMutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol. (2009) 54:930–41. 10.1016/j.jacc.2009.05.038
57.
NortonNLiDRiederMJSiegfriedJDRampersaudEZüchnerSet alGenome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet. (2011) 88:273–82. 10.1016/j.ajhg.2011.01.016
58.
MillerDTLeeKAbul-HusnNSAmendolaLMBrothersKChungWKet alACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. (2022) 24:1407–14. 10.1016/j.gim.2022.04.006
59.
LindholmMEJimenez-MoralesDZhuHSeoKAmarDZhaoCet alMono- and biallelic protein-truncating variants in alpha-actinin 2 cause cardiomyopathy through distinct mechanisms. Circ Genom Precis Med. (2021) 14:e003419. 10.1161/CIRCGEN.121.003419
60.
HanPLiWLinC-HYangJShangCNuernbergSTet alA long noncoding RNA protects the heart from pathological hypertrophy. Nature. (2014) 514:102–6. 10.1038/nature13596
61.
KellyMACaleshuCMoralesABuchanJWolfZHarrisonSMet alAdaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s inherited cardiomyopathy expert panel. Genet Med. (2018) 20:351–9. 10.1038/gim.2017.218
62.
ZhangQChenJQinYWangJZhouL. Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia. Channels. (2018) 12:201–18. 10.1080/19336950.2018.1499368
63.
González-MariscalLGallego-GutiérrezHGonzález-GonzálezLHernández-GuzmánC. ZO-2 is a master regulator of gene expression, cell proliferation, cytoarchitecture, and cell size. Int J Mol Sci. (2019) 20(17):4128. 10.3390/ijms20174128
64.
ArimuraTTakeyaRIshikawaTYamanoTMatsuoATatsumiTet alDilated cardiomyopathy-associated FHOD3 variant impairs the ability to induce activation of transcription factor serum response factor. Circ J. (2013) 77:2990–6. 10.1253/circj.CJ-13-0255
65.
OchoaJPSabater-MolinaMGarcía-PinillaJMMogensenJRestrepo-CórdobaAPalomino-DozaJet alFormin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy. J Am Coll Cardiol. (2018) 72:2457–67. 10.1016/j.jacc.2018.10.001
66.
WootenECHeblVBWolfMJGreytakSROrrNMDraperIet alFormin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. (2013) 6:10–8. 10.1161/CIRCGENETICS.112.965277
67.
DingYYangJChenPLuTJiaoKTesterDJet alKnockout of SORBS2 protein disrupts the structural integrity of intercalated disc and manifests features of arrhythmogenic cardiomyopathy. J Am Heart Assoc. (2020) 9:e017055. 10.1161/JAHA.119.017055
68.
MartinoFVaradarajanNMPerestreloARHejretVDurikovaHVukicDet alThe mechanical regulation of RNA binding protein hnRNPC in the failing heart. Sci Transl Med. (2022) 14:eabo5715. 10.1126/scitranslmed.abo5715
69.
D’UvaGAharonovALauriolaMKainDYahalom-RonenYCarvalhoSet alERBB2 Triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol. (2015) 17:627–38. 10.1038/ncb3149
70.
WaduguBKühnB. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol. (2012) 302:H2139–47. 10.1152/ajpheart.00063.2012
71.
OdieteOHillMFSawyerDB. Neuregulin in cardiovascular development and disease. Circ Res. (2012) 111:1376–85. 10.1161/CIRCRESAHA.112.267286
72.
SeemannESunMKruegerSTrögerJHouWHaagNet alDeciphering caveolar functions by syndapin III KO-mediated impairment of caveolar invagination. Elife. (2017) 6:e29854. 10.7554/eLife.29854
73.
BiH-LZhangX-LZhangY-LXieXXiaY-LDuJet alThe deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor. Sci Adv. (2020) 6(16):eaax4826. 10.1126/sciadv.aax4826
74.
YamadaNAsanoYFujitaMYamazakiSInanobeAMatsuuraNet alMutant KCNJ3 and KCNJ5 potassium channels as novel molecular targets in bradyarrhythmias and atrial fibrillation. Circulation. (2019) 139:2157–69. 10.1161/CIRCULATIONAHA.118.036761
75.
CirinoALLakdawalaNKMcDonoughBConnerLAdlerDWeinfeldMet alA comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. Circ Cardiovasc Genet. (2017) 10:e001768. 10.1161/CIRCGENETICS.117.001768
76.
TonryCLindenKCollierPLedwidgeMMcDonaldKCollinsBCet alProteomic characterisation of heart failure reveals a unique molecular phenotype for hypertrophic cardiomyopathy. Biomedicines. (2024) 12:1712. 10.3390/biomedicines12081712
77.
GarmanyRBosJMDasariSJohnsonKLTesterDJGiudicessiJRet alProteomic and phosphoproteomic analyses of myectomy tissue reveals difference between sarcomeric and genotype-negative hypertrophic cardiomyopathy. Sci Rep. (2023) 13:14341. 10.1038/s41598-023-40795-1
Summary
Keywords
hypertrophic cardiomyopathy, MYH7, modifier, genome sequencing, left ventricular hypertrophy
Citation
Lindholm ME, Abramowitz S, Waggott DM, Grove ME, Dewey FE, Pan C, Pavlovic A, Shang C, Huang Y, Bensabath L, Goldfeder RL, Cordero P, Erbilgin A, Priest JR, Chaib H, Puckelwartz MJ, Day SM, McNally EM, Cappola T, Dorn GW, Ashley EA and Wheeler MT (2025) Identification of candidate cardiomyopathy modifier genes through genome sequencing and RNA profiling. Front. Cardiovasc. Med. 12:1546493. doi: 10.3389/fcvm.2025.1546493
Received
17 December 2024
Accepted
03 March 2025
Published
28 July 2025
Volume
12 - 2025
Edited by
Yeong-Renn Chen, Northeast Ohio Medical University, United States
Reviewed by
Chia-Feng Liu, Cleveland Clinic, United States
Patrick Kang, Northeast Ohio Medical University, United States
Updates
Copyright
© 2025 Lindholm, Abramowitz, Waggott, Grove, Dewey, Pan, Pavlovic, Shang, Huang, Bensabath, Goldfeder, Cordero, Erbilgin, Priest, Chaib, Puckelwartz, Day, McNally, Cappola, Dorn, Ashley and Wheeler.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Matthew T. Wheeler wheelerm@stanford.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.